A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)

UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer

(2015) Yoshinori Miyata et al.   International Journal of Clinical Oncology

A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese Patients With Metastatic Colorectal Cancer (BIX Study)

(2014) Y. Hamamoto et al.   ONCOLOGIST

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

(2013) W. Schmiegel et al.   ANNALS OF ONCOLOGY

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

(2013) M. Ducreux et al.   EUROPEAN JOURNAL OF CANCER

Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians

(2013) X Liu et al.   PHARMACOGENOMICS JOURNAL

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis

(2012) Mafalda M Dias et al.   PHARMACOGENOMICS

Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know

(2010) Mizuki Nishino et al.   AMERICAN JOURNAL OF ROENTGENOLOGY